GILD Obtains Positive CHMP Opinion for Liver Disease Drug [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
Agency's Committee for Medicinal Products for Human Use (CHMP) for its liver disease drug seladelpar, which is expected to be approved in the first quarter of 2025. The CHMP recommended seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) or as monotherapy in adults who cannot tolerate UDCA. The positive opinion is based on the RESPONSE Study, which showed significant improvements in liver function and symptoms. This potential approval will strengthen Gilead's liver disease portfolio and follows the FDA's accelerated approval of seladelpar in the US under the brand name Livdelzi. Generated by Yahoo Finance AI Yahoo Finance used generative AI to summarize key information from this article. Some details may be inaccurate. We take that seriously. Reporting mistakes helps us improve these summaries. Was this helpful? Yes No Gilead Sciences, Inc . GILD announced that the Committee for Medicinal Products for Human Use
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences to Present at Upcoming Investor ConferenceBusiness Wire
- Gilead Sciences (GILD) Gains As Market Dips: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Lightning Round: Uber is attractive at these levels, says Jim Cramer [CNBC]CNBC
- GILD Signs Collaboration Agreement With Terray Therapeutics [Yahoo! Finance]Yahoo! Finance
- Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 11/6/24 - Beat
GILD
Sec Filings
- 12/17/24 - Form 4
- 12/16/24 - Form 4
- 12/16/24 - Form 144
- GILD's page on the SEC website